General

Showing 1873–1888 of 2270 results

Article: PP13 Targeting Protein Arginine Methyltransferase PRMT5 in high-risk multiple myeloma: a new treatment strategy?
€3.03 Add to cart
Article: PP14 MRD analysis by next-generation sequencing in multiple myeloma and pediatric acute lymphoblastic leukemia
€3.03 Add to cart
Article: PP15 Development of reticulocytosis through inhibition of terminal erythroid maturation by carfilzomib treatment in multiple myeloma
€3.03 Add to cart
Article: PP16 Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder
€3.03 Add to cart
Article: PP17 Targeting of the histone methyltransferases G9a and GLP in multiple myeloma
€3.03 Add to cart
Article: PP19 NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction Independently of Previous Hematologic Response
€3.03 Add to cart
Article: PP2.1 Immunomodulatory effects of rapamycin in Graft versus Host Disease
€3.03 Add to cart
Article: PP2.2 Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in EXELS
€3.03 Add to cart
Article: PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation
€3.03 Add to cart
Article: PP2.4 Identifying infectious triggering factors even in the presence of known predisposing diseases is mandatory in hemophagocytic lymphohistiocytosis, a review of 35 cases in two Belgian hospitals
€3.03 Add to cart
Article: PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group
€3.03 Add to cart
Article: PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium
€3.03 Add to cart
Article: PP21 The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study
€3.03 Add to cart
Article: PP22 Maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
€3.03 Add to cart
Article: PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy
€3.03 Add to cart
Article: PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?
€3.03 Add to cart

Article: PP13 Targeting Protein Arginine Methyltransferase PRMT5 in high-risk multiple myeloma: a new treatment strategy?

Article: PP14 MRD analysis by next-generation sequencing in multiple myeloma and pediatric acute lymphoblastic leukemia

Article: PP15 Development of reticulocytosis through inhibition of terminal erythroid maturation by carfilzomib treatment in multiple myeloma

Article: PP16 Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder

Article: PP17 Targeting of the histone methyltransferases G9a and GLP in multiple myeloma

Article: PP19 NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction Independently of Previous Hematologic Response

Article: PP2.1 Immunomodulatory effects of rapamycin in Graft versus Host Disease

Article: PP2.2 Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in EXELS

Article: PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation

Article: PP2.4 Identifying infectious triggering factors even in the presence of known predisposing diseases is mandatory in hemophagocytic lymphohistiocytosis, a review of 35 cases in two Belgian hospitals

Article: PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group

Article: PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium

Article: PP21 The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study

Article: PP22 Maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease

Article: PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy

Article: PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?